ArticleJournal of hepatocellular carcinoma2022

Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study.

Jingjun Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.